Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...

Immuneering Corporation (IMRX) stock gains as company announces positive data for pancreatic cancer treatment and plans to expand its mid-stage program. Read more here.

From jaundice and uncontrolled blood sugars to cancer concerns, each scenario highlights the importance of patient education ...

Deep faith powered the superhero perseverance that drove Jason Potsander. Now, his three kids have inherited his love of ...

Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer patients.

Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...